Condition: Prostate Cancer · Sponsor: Palette Life Sciences, Inc.
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.
This description comes directly from the study's public registry record.
Joseph Onokwai, MD, MPH, PhD · 7738864397 · v-jonokwai@palettelifesciences.com
Cliff Kline · 8054569653 · cliff.kline@teleflex.com
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Summit Health | Clifton, New Jersey, United States | Recruiting |
| Urology Austin | Austin, Texas, United States | Recruiting |
| Houston Metro Urology | Houston, Texas, United States | Active Not Recruiting |
| GenesisCare Ringwood | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06496256